Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Additional blood sampling.
- Кому может быть актуально
- Состояния в реестре: Myeloproliferative Neoplasm, Myeloproliferative Disorders. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Франция
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)
Обзор
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.
Подробное описание
JAK2V617F positive myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells characterized by an increased risk of thrombosis, the main cause of morbidity and mortality in these patients. Classical risk factors for thrombosis include a prior thrombotic event and age over 60. However, these criteria are often insufficient, as some patients who receive treatment continue to experience thrombosis, while others may be overtreated based solely on age. Recent studies have highlighted the role of neutrophil extracellular traps (NETs) in thrombosis, suggesting that NETosis, the process of NET formation, contributes to the activation of hemostasis and coagulation. Increased levels of NETs have been observed in patients with MPNs, particularly those with a history of thrombosis. Aspirin has shown a potential to reduce NET formation and the occurrence of thrombosis by inhibiting platelet-triggered NETosis. This study aims to prospectively evaluate the prognostic value of NETosis markers to predict thrombosis and optimize thrombotic prevention strategies in JAK2V617F-positive MPN patients.
The AVATARE ancillary study is linked to the AVAJAK clinical trial, which compares the efficacy of aspirin versus direct oral anticoagulants (DOACs) in preventing thrombotic events. Patients included in the AVATARE study will undergo venous blood sampling at baseline (T0) and 12 months (T1) for NETosis markers, such as calprotectin and citrullinated histone H3 (H3Cit). Participants will be followed up for 24 months. Clinical data, including the occurrence of venous and arterial thrombotic events, will be collected during the study period. Blood samples will be taken at inclusion (T0) and at 12 months (T1). The progression of NETosis markers will be monitored, and their correlation with thrombotic outcomes will be assessed to understand the potential role of these markers in predicting future thrombotic events.
Вмешательства
- Биопрепарат Additional blood sampling
At inclusion (T0) and at 12 months (T1), venous blood will be drawn for plasma markers of NETosis
Первичные конечные точки
- Serum calprotectin concentration [Срок оценки: At T0 (inclusion)]
Вторичные конечные точки (4)
- Serum calprotectin concentration [Срок оценки: At T1 (12 months post-inclusion)]
- Serum concentration of citrullinated histone H3 (H3Cit) [Срок оценки: At T1 (12 months post-inclusion)]
- Plasma citrullinated histone 3 concentration [Срок оценки: At T0 (inclusion)]
- Plasma citrullinated histone 3 concentration [Срок оценки: At T1 (12 months post-inclusion)]
Критерии участия
Критерии включения
- Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
- JAK2V617F mutation with an allelic burden greater than 1%
- High risk of thrombosis (age over 60 years or prior thrombotic event)
- Diagnosis of MPN within the last 12 months
- Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
- Affiliation with social security
- Signed informed consent
Критерии исключения
- Severe hepatic or renal insufficiency (Creatinine clearance <30ml/min)
- Patients under legal protection (guardianship or curatorship)
- Patients under heparin treatment at inclusion
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Нерандомизированное
- Модель
- Параллельные группы
- Маскирование
- Простое слепое
- Основная цель
- Диагностика
Центры проведения
Франция · 15 центров
- CHU d'Angers, Service des maladies du Sang — Angers
- CH de la Côte Basque, Service Hématologie — Bayonne
- CHU de Bordeaux, Service Hématologie Biologique — Bordeaux
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire — Bordeaux
- CHU de Brest, Service Hématologie et Hémostase Clinique — Brest
- APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire — Créteil
- CHD de Vendée, Service Onco-hématologie — La Roche-sur-Yon
- APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire — Le Kremlin-Bicêtre
- … и ещё 7 центров
Идентификаторы
NCT: NCT07119970 · CHUBX 2023/91